Start saving now

Eligible* commercially insured patients may
pay as little as a 
 $25 COPAY FOR UP TO
A 90-DAY SUPPLY For first Rx and eligible refills

START SAVING NOW
Woman in a yoga pose gesturing V with her fingers. vyzulta-vshape-yoga

Not an actual patient.

Join our VYZULTA Community!

*Fields marked with an asterisk are required.

By submitting your information you confirm you have read and agree with the terms of our Privacy Policy and Legal Notice.

By submitting your information you confirm you have read and agree with the terms of our Privacy Policy and Legal Notice.

I would like to learn more about VYZULTA, information about glaucoma, refill and medication reminders, and more support for my treatment journey.I agree to receive marketing communications, such as email communication, from Bausch + Lomb and its affiliates regarding information and offerings relating to its products like VYZULTA. I understand that I may withdraw my consent by visiting B+L Communication Opt Out. By checking the box, I request and consent to receive text alerts, including marketing and promotional messages, from or on behalf of Bausch & Lomb Americas Inc. at any telephone number I have provided. I understand that my consent is not a condition of purchasing any goods or services. Message and data rates may apply. Message frequency varies. Text "STOP" to stop receiving text alerts. Text "HELP" for help. See Eligibility Criteria/Terms and Conditions, Mobile Terms and Conditions, and Privacy Policy.
I would like to learn more about VYZULTA, information about glaucoma, refill and medication reminders, and more support for my treatment journey.I agree to receive marketing communications, such as email communication, from Bausch + Lomb and its affiliates regarding information and offerings relating to its products like VYZULTA. I understand that I may withdraw my consent by visiting B+L Communication Opt Out. By checking the box, I request and consent to receive text alerts, including marketing and promotional messages, from or on behalf of Bausch & Lomb Americas Inc. at any telephone number I have provided. I understand that my consent is not a condition of purchasing any goods or services. Message and data rates may apply. Message frequency varies. Text "STOP" to stop receiving text alerts. Text "HELP" for help. See Eligibility Criteria/Terms and Conditions, Mobile Terms and Conditions, and Privacy Policy.
I consent to the disclosure of my health-related personal data, including claims activity data, to Bausch + Lomb and its affiliates. I further agree to the collection, use, and disclosure of my health-related personal data by Bausch + Lomb and its affiliates for patient education and marketing purposes, as further described in Bausch + Lomb's Legal Notice and Privacy Policy. I understand that I can withdraw my consent by submitting a verifiable consumer request to u.s.privacy@bausch.com or by calling 1-800-553-5340.
I consent to the disclosure of my health-related personal data, including claims activity data, to Bausch + Lomb and its affiliates. I further agree to the collection, use, and disclosure of my health-related personal data by Bausch + Lomb and its affiliates for patient education and marketing purposes, as further described in Bausch + Lomb's Legal Notice and Privacy Policy. I understand that I can withdraw my consent by submitting a verifiable consumer request to u.s.privacy@bausch.com or by calling 1-800-553-5340.
Back to top

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
  • Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
  • Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
  • Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
  • Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
  • If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
  • The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

*Offer not valid for patients whose prescriptions are reimbursed by any federal or state healthcare program, including Medicaid, Medicare, TRICARE, or any other federal or state healthcare program. Other restrictions apply. See complete Eligibility Criteria and Terms and Conditions at BauschCopayProgram.com. Ninety-day supply to be prescribed as 3 bottles of 2.5 mL solution each. Ninety-day supply copay offer only applies if each of the three 2.5-mL bottles is covered by a patient’s commercial insurance.
†Exclusively at Walgreens and other participating independent pharmacies, eligible commercially insured patients may pay as little as a $25 copay.
SEE MOREExpand

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.